{name}
{subtitle}
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~33 mi. (Leeuwarden, Netherlands, +192 more cities)
facility
Medische Centrum Leeuwarden
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~57 mi. (Alkmaar, Netherlands, +226 more cities)
facility
Noordwest Ziekenhuisgroep NWZ ( Site 0468)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
city
~64 mi. (Amsterdam, Netherlands, +89 more cities)
facility
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL) ( Site 1351)
biomarker
ER Positive, +2 more biomarkers
drug
capecitabine, +4 more drugs
drug type
chemotherapy, +1 more type
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~64 mi. (Amsterdam, Netherlands, +140 more cities)
facility
AMC ( Site 0438)
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
city
~64 mi. (Amsterdam, Netherlands, +127 more cities)
facility
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)
drug
cetuximab, +3 more drugs
drug type
chemotherapy, +1 more type